Gelonghui, April 17, 丨 Ed Biotech (300685.SZ) held a conference call on April 16, 2024. Regarding the “status of newly approved MSI products,” the company replied that tumor immunotherapy is increasingly becoming an important treatment for precision cancer treatment. MSI and PDL1 (the company's PD-L1 product was approved and marketed by the NMPA in March 2022) are currently the most clinically recognized biomarkers for predicting the efficacy of immunopharmaceuticals. The company's MSI test kit is the first pan-solid tumor immunotherapy companion diagnosis approved for marketing in China. In 2024, we will rapidly advance pre-testing and acceptance of MSI products.
艾德生物(300685.SZ)：MSI检测试剂盒是国内首个批准上市的泛实体瘤免疫治疗伴随诊断
Ed Biotech (300685.SZ): The MSI test kit is the first pan-solid tumor immunotherapy companion diagnosis approved for marketing in China
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.